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Blood-based bioenergetic profiling provides a minimally invasive assessment of mitochondrial health shown to be related to key
features of aging. Previous studies show that blood cells recapitulate mitochondrial alterations in the central nervous system
under pathological conditions, including the development of Alzheimer’s disease. In this study of nonhuman primates, we focus
on mitochondrial function and bioenergetic capacity assessed by the respirometric profiling of monocytes, platelets, and frontal
cortex mitochondria. Our data indicate that differences in the maximal respiratory capacity of brain mitochondria are reflected
by CD14+ monocyte maximal respiratory capacity and platelet and monocyte bioenergetic health index. A subset of nonhuman
primates also underwent [18F] fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to assess brain glucose
metabolism. Our results indicate that platelet respiratory capacity positively correlates to measures of glucose metabolism in
multiple brain regions. Altogether, the results of this study provide early evidence that blood-based bioenergetic profiling is
related to brain mitochondrial metabolism. While these measures cannot substitute for direct measures of brain metabolism,
provided by measures such as FDG-PET, they may have utility as a metabolic biomarker and screening tool to identify
individuals exhibiting systemic bioenergetic decline whomay therefore be at risk for the development of neurodegenerative diseases.
1. Introduction
There is mounting evidence that blood-based respirometric
profiling can report on systemic bioenergetic capacity. Previ-
ous studies link mitochondrial parameters measured in
peripheral blood mononuclear cells (PBMCs), made up of
monocytes and lymphocytes, and platelets to various age-
related diseases and disorders such as AD, diabetes, and
frailty [1–6]. Our previous studies have shown that the respi-
rometric profiles of blood cells are related to features of aging
that are associated with morbidity and mortality, including
reduced physical ability and inflammation [7, 8]. More
recently, we reported that blood cell respirometry reflects
the bioenergetic capacity of highly metabolically active tis-
sues such as skeletal and cardiac muscles [9]. These studies
support potential diagnostic applications of minimally inva-
sive, blood-based measures of mitochondrial function [10].
The goal of this studywas to expandon this body of knowledge
by investigating the relationships of blood cell respirometry to
measures of brain bioenergetics and metabolism.
Highlymetabolically active tissues are particularly suscep-
tible to bioenergetic decline. The adult brain, which accounts
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for just~2%of total bodyweight, utilizes~20%of total bodyO2
consumption and ~60% of total body glucose and requires a
daily energy input of ~420 kcal [11, 12]. This exceptionally
high metabolic demand makes the brain remarkably sensitive
to the deleterious effects of mitochondrial dysfunction. In
2004, Swerdlow and Khan proposed the “mitochondrial cas-
cade hypothesis” for the development of sporadic late-onset
AD, stating that mitochondrial dysfunction is the primary
event leading to the deposition of senile plaques and neurofi-
brillary tangles that are hallmarks of this disease [13]. Over
the past decade, it has been increasingly recognized that
changes inmitochondrial function are apparent at the earliest
presymptomatic stages ofADand related to the progression of
disease [14].Multiple studies link the deposition of amyloid-β
(Aβ) to alterations in mitochondrial bioenergetics, for
example, depolarization, uncoupling of the electron transport
chain (ETC), reducedATP production, and increased reactive
oxygen species generation [15–18]. Studies of patients and
animalmodels indicate thatADis associatedwith the accumu-
lation of amyloid precursor protein (APP) and Aβ on brain
mitochondria, leading to bioenergetic changes [19–24].
Greater AD risk is associated with reduced cerebral glucose
metabolic rate, measured by [18F] fluorodeoxyglucose posi-
tron emission tomography (FDG-PET), which can appear
years before dementia onset [25, 26]. Thus, FDG-PET has
emerged as a powerful method for the early detection of AD
and may help differentiate mild AD from other forms of
dementia [27, 28]. A subset of primates utilized in this project
underwent brain FDG-PET imaging, providing us with a
unique opportunity to obtain preliminary data on the
relationships between blood cell respirometry and brain
glucose metabolism.
Multiple lines of evidence indicate that peripheral
mitochondrial dysfunction accompanies changes in brain
mitochondria in AD. Analysis of white blood cells from
patients with early AD shows that the expression of mito-
chondrial respiratory complex I–V genes and subunits of
the core mitochondrial ribosome complex are decreased
compared to controls [29]. The authors report that these dif-
ferences mirror changes observed in AD brains. Circulating
lymphocytes from patients with AD also exhibit a patholog-
ical pattern of mitochondrial dysfunction and increased
oxidative damage [30–32]. Platelet mitochondrial function
has been shown to be impaired in patients with mild
cognitive impairment (MCI) and AD compared to healthy
age-matched controls [1, 33, 34]. Several groups are now
exploring the use of blood cells for early diagnosis of AD
[35–37]. The goal of this project is to expand on this growing
body of knowledge by examining the relationships between
brain bioenergetics and metabolism with CD14+ monocyte
and platelet mitochondrial function.
First described in 1955, respirometry remains the gold
standard assessment of mitochondrial function and is able
to capture the cumulative effects of intrinsic and extrinsic
factors on bioenergetic capacity [29–31]. In this study, we
utilized mitochondrial respirometry to assess mitochondrial
function in circulating cells and isolated brain (frontal cortex)
mitochondria. The assessments were performed on nonhu-
man primates, representing various levels of cardiometabolic
health across young and old age groups. This broad selection
criterion was utilized in order to maximize potential differ-
ences in systemic bioenergetic capacity between animals. We
tested the hypothesis that the respirometric profile of circu-
lating cells reflects differences in systemic bioenergetic
capacity, including differences in brain bioenergetics and
metabolism. This hypothesis is based on the recognition that
blood cells are continuously exposed to circulating factors
such as inflammatory cytokines, redox stress [36], and
recently described mitokines [37], which can affect mito-
chondrial function across different tissues and organ systems.
Our goal is to examine blood-based bioenergetic profiling as a
potential biomarker for changes in brain metabolism that has
been linked to the development of neurodegenerative diseases
such as AD.
2. Materials and Methods
2.1. Animals. Female vervet/African green monkeys (Chloro-
cebus aethiops sabaeus) ranging in age from 8.2 to 23.4 years
were utilized for this study. Animals were socially housed in
stable groups of 11–49 in housing units with indoor and out-
door access of approximately 28m2 indoors and 111m2 out-
doors which contained perches, platforms, elevated climbing
structures, and a base composed of smooth stones. Prior to
the study, 7 of the 18 animals were moved to indoor housing
(pair- or individually housed). All animals were fed with a
standard monkey chow diet (Lab Diet 1538) that was sup-
plemented with fruits and vegetables 5 times per week.
Water was available ad libitum. Immediately prior to nec-
ropsy, blood samples were collected from anesthetized
animals. Frontal cortex tissues were taken during necropsy.
2.2. BodyMass and Blood Glucose. Body weight wasmeasured
at the time of necropsy. Fasting glucose was determined via an
autoanalyzer (ACEAlera) fromAlfaWassermannDiagnostic
Technologies (West Caldwell, NJ). These analyses were
performed in theWake Forest ComparativeMedicineClinical
Chemistry and Endocrinology Laboratory 4–12months prior
to necropsy.
2.3. Isolation of Blood Cells. Acid citrate dextrose (ACD)
tubes (Vacutainer; Becton Dickinson, Franklin Lakes, NJ)
were used to collect 8ml of blood from fasted monkeys.
Samples were maintained at room temperature and proc-
essed immediately to obtain platelet and CD14+ monocyte
populations. The method for isolating platelets and CD14+
monocytes has been described [38]. Whole blood was centri-
fuged at 500×g for 15 minutes in ACD tubes with no brake at
room temperature. Platelet rich plasma was removed and
centrifuged at 1500×g for 10 minutes to isolate platelets
which were washed in phosphate-buffered saline (PBS) with
prostaglandin E1 (PGE1; Cayman Chemical, Ann Arbor,
MI) and resuspended in extracellular flux (XF) assay buffer
(Seahorse Biosciences, North Billerica, MA) containing
1mMNa+ pyruvate, 1mMGlutaMAX (Gibco, Grand Island,
NY), 11mM D-glucose, and PGE1 (pH7.4). At the same
time, the peripheral blood mononuclear cell (PBMC) layer
was extracted, diluted in RPMI 1640 (Gibco), and layered
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onto 3mL of polysucrose solution at a density of 1.077 g/mL
(Sigma Histopaque®-1077, St. Louis, MO) in 15mL centri-
fuge tubes. This was centrifuged at 700×g for 30 minutes
with no brake to purify the PBMCs and remove red blood
cells. The purified PBMC layer was obtained and washed
in PBS. Finally, CD14+ monocytes were isolated using
CD14-labeled magnetic microbeads (Miltenyi Biotec, San
Diego, CA) according to the manufacturer’s instructions
using modified RPMI 1640+ fatty acid free bovine serum
albumin (BSA) media. Platelets and monocytes were
counted via a hemacytometer. Monocytes were washed
again, using the same buffer, and resuspended in XF
assay buffer without PGE1.
2.4. Respirometry of Blood Cells. Respirometry of blood cells
was carried out using the Seahorse XF24-3 extracellular flux
analyzer (Seahorse Bioscience, Agilent) with 250,000 mono-
cytes and ~25,000,000 platelets in quadruplicate [39]. The
methods of bioenergetic profiling have been described before
[40]. Basal oxygen consumption rate (OCR) measures were
monitored prior to any chemical additions. Then, sequential
additions of oligomycin (750 nM), carbonyl cyanide-4-
(trifluoromethoxy) phenylhydrazone (FCCP; 1μM), and
antimycin A+ rotenone (A/R; both 1μM) (all from Sigma-
Aldrich) were added with measurements taken after each.
FCCP stimulates the maximal OCR. The difference between
themaximal OCR and basal OCR is termed the reserve capac-
ity which has been reported on previously [41, 42]. The differ-
ence between basal and oligo is theATP-linkedOCR [43]. The
difference between the oligomycin-induced respiration
(oligo) and A/R is reported as leak respiration. The bioener-
getic health index (BHI) was calculated according to the
equation from Chacko et al. [38]. Monocyte respiration is
reported as pmol/min/250,000 cells and platelet respiration
was normalized to total protein content (mg), determined by
Pierce BCA assay (Thermo Fisher Scientific, Grand Island,
NY), and reported as pmol/min/mg protein.
2.5. FDG-PET Imaging. Animals were anesthetized with
ketamine for transfer to the imaging suite. Animals were then
intubated and maintained on isoflurane for the duration of
the imaging. An indwelling venous catheter was introduced
into the saphenous vein for continuous blood sampling
during scan acquisition and a second catheter placed in the
contralateral saphenous vein for the injection of 5mCi of
tracer. Blood samples were obtained at 3, 8, 16, 24, 35, and
55min after FDG infusion.
18F-FDG-PET imaging used the time frames 12× 10 sec,
8× 30 sec, 6× 4 min, and 3× 10 min, for a total length of
60min. PET images were preprocessed and coregistered to
T1-weighted anatomical magnetic resonance (MR) images
using a cross-modality 3D image fusion tool in PMOD 3.5.
MR imageswere acquired ona3TSiemens SkyraMRI scanner
using a 3D volumetric MPRAGE sequence (TR=2700msec;
TE=3.39msec; TI = 880msec; FA=8 degrees; and 160 slices,
voxel dimension=0.5× 0.5× 0.5mm). Coregistered PET
images were corrected for partial-volume effect with themod-
ifiedMüller-Gartnermethod. Using the PMOD3.5 pixel-wise
kineticmodeling tool, parametric images of cerebralmetabolic
rate of glucose (CMRg) were produced. CMR quantification
included an arterial input function, determined by tracing
regions of interest on the internal carotid arteries with the aid
of coregistered MR images. The lumped constant used for
the CMRg calculation was set to 0.344.
The CMR data for this study were processed with two
atlases. Data for components of the vervet anterior cingulate
cortex (Brodmann areas 24, 25, and 32), amygdala, and the
anterior/posterior hippocampus were defined with methods
described in [44]. Data for the frontal cortex were defined
from a well-established nonhuman primate atlas, UNC-
parcellation [45]. Complete methods for regional CMR
generation with the two atlases can be found at Maldjian
et al. 2015 [46].
2.6. Euthanasia. Ketamine (10–15mg/kg, IM) followed by
sodium pentobarbital (60–100mg/kg, IV) was the method
of euthanasia used to attain deep surgical anesthesia followed
by exsanguination in accordance with guidelines established
by the Panel on Euthanasia of the American Veterinary
Medical Association. All procedures were approved and
performed according to the guidelines of state and federal
laws, the US Department of Health and Human Services,
and the Animal Care and Use Committee of Wake Forest
School of Medicine.
2.7. Isolation of Mitochondria from the Frontal Cortex.
Methods of isolating mitochondria have been described pre-
viously and were modified slightly for frontal cortex samples
[47]. For each animal, ~50mg of tissue was minced into small
pieces and resuspended in Chappell-Perry buffer I (CP I)
containing ~1mg/ml Nagarse (Sigma-Aldrich) for 5 minutes
at room temperature. Frontal cortex samples were homoge-
nized by 6 strokes using a glass-on-glass dounce homoge-
nizer. The homogenate was washed with an equal volume
of CP I and 2x volume of CP II buffer by centrifuging at
600×g at 4°C for 10 minutes (Eppendorf Centrifuge 5804R,
Eppendorf AG, Hamburg, Germany). The supernatant was
then filtered through cheese cloth and subsequently centri-
fuged at 10,000×g at 4°C for 10 minutes using a Beckman
centrifuge, model J2-21M Induction drive centrifuge
(Beckman-Coulter, Inc., Brea, CA). The mitochondrial pellet
was washed twice more with the same conditions then resus-
pended inmitochondrial assay solution (mannitol and sucrose
buffer: MAS; sucrose 35mM, mannitol 110mM, KH2PO4
2.5mM,MgCl2 2.5mM,HEPES 1.0mM, EGTA 0.5mM, fatty
acid free BSA 0.10%, and pH7.4) prior to respirometry. The
protein content of the purified frontal cortex mitochondria
was determined by Pierce BCA assay (Thermo Fisher
Scientific, Grand Island, NY). From 50mg of tissue, ~500μg
of purified mitochondria was obtained.
2.8. Respirometry of Isolated Mitochondria. Respirometry of
frontal cortex-isolated mitochondria was performed using
the XF24-3 as previously described in other tissues [47, 48].
This protocol was optimized for respiration driven by
complex 2, which provides consistently higher values in
accordance with previous reports [48]. Chemical additions
were prepared in 1x MAS at 10x the final concentration
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required (2mM ADP, 2μM oligomycin, 6μM FCCP, and
2μM antimycin A). Isolated mitochondria (5μg) were plated
in quadruplicate in 50μl and attached via centrifugation at
2000×g at 4°C for 20 minutes. After centrifugation, 450μl
of 1x MAS containing succinate (10mM) and rotenone
(2μM) was gently added to each well to a total volume of
500μl. The respirometric profiling procedure first stimulates
maximal State 3 respiration with ADP, followed by inhibi-
tion of ATP synthase with oligo, providing the State 4o.
Then, FCCP is injected which uncouples the electron trans-
port chain to induce another measure of maximal respira-
tion. Finally, antimycin A is titrated to block the flow of
electrons at complex III and halt respiration. The respiration
of isolated mitochondria is reported as pmol/min/5μg
mitochondrial protein.
2.9. Statistical Analyses. Shapiro-Wilk tests ensured that all
variables were normally distributed. Pearson correlation
coefficients were assessed between all variables, and partial
correlations for age, weight, and glucose level were also
assessed. Analyses of monocyte and platelet respirometry
were focused on maximal uncoupled respiration induced
by FCCP, reserve capacity (calculated by subtracting basal
from maximal respiration), and BHI. In order to provide a
corresponding measure from contemporaneous respiromet-
ric profiling of brain mitochondria, analyses of frontal
cortex mitochondrial respiration were focused on maximal
uncoupled respiration induced by FCCP. Analyses of brain
metabolism by FDG-PET focused on multiple brain regions
in order to account for potential regional differences. Signif-
icance was set at an α-level of 0.05. The analyses were
performed (SPSS v22; Armonk, NY).
3. Results
3.1. Characterization of Primates. Female vervets were
selected to represent a wide range of metabolic health status
as evidenced by insulin resistance as well as body mass indi-
ces from lean to obese across young and old age groups. Age,
body weight, and fasting glucose are summarized in Table 1.
A total of 15 vervets were studied with a mean age of 15.2
years. Ages ranged from 8.2 to 23.4 years. The mean weight
of the animals was 4.8 kg, ranging from 3.3–6.9 kg. Fast-
ing plasma glucose level averaged 128.6mg/dL, ranging
from 61–319mg/dL. Bioenergetic characteristics of mono-
cytes, platelets, and isolated brain mitochondria are tabulated
in Table 2. Large standard deviations reflect the intended
diversity of our cohort.
3.2. Pearson and Partial Correlations betweenMonocyte/Platelet
Respiration and the Bioenergetic Capacity of Mitochondria
Isolated from the Frontal Cortex Tissue. Pearson correlation
coefficients were used to compare blood cell bioenergetic
parameters with brain-isolated mitochondrial respiration.
The relationships between monocyte respiratory parameters
(maximal OCR, reserve capacity, and OCR) and the maximal
respiration of mitochondria isolated from the frontal cortex
tissue are summarized in Table 3. Representative regression
plots are shown in Figure 1. Maximal FCCP-linked respiration
in monocytes was significantly positively correlated with max-
imal FCCP-linked respiration measured from brain mitochon-
dria (R = 0 59, p = 0 04). This relationship remained significant
even when controlling for age, body weight, and plasma
glucose concentration. Similar results are observed when
comparing monocyte reserve capacity to brain mitochondria;
however, statistical significance was only evident when
controlling for glucose (R = 0 65, p = 0 02). BHI was signifi-
cantly positively correlatedwith brainmitochondrial respiration
Table 1: Demographics: Chlorocebus aethiops sabaeus.
N = 15 Mean Range SD
Age (yrs) 15.2 8.2–23.4 6.20
Weight (kg) 4.8 3.3–6.9 0.88
Fasting glucose (mg/dL) 128.6 61–319 70.31
Table 2: Respiratory parameters for monocytes, platelets, and
isolated brain mitochondria.
Mean SD
Monocyte respiration (pmol/min/250,000 cells)
Basal 50.64 20.82
Maximal 98.65 42.80
Leak 6.25 9.30
Nonmitochondrial 22.08 14.02
Reserve 48.02 27.56
Bioenergetic health index 1.58 1.50
Platelet respiration (pmol/min/mg protein)
Basal 210.04 87.71
Maximal 419.93 161.31
Leak 17.95 28.38
Nonmitochondrial 85.92 20.76
Reserve 209.88 88.46
Bioenergetic health index 2.40 0.85
Brain-isolated mitochondria (pmol/min/5 μg
mitochondrial protein)
State 3 250.31 112.86
State 4o 66.01 46.83
Maximal FCCP-linked 268.42 102.87
Nonmitochondrial 22.58 42.50
Monocyte: N = 13; platelet: N = 15; isolated brain mitochondria: N = 15.
Table 3: Pearson and partial correlations between CD14+
monocyte and isolated brain mitochondrial respiration.
Frontal cortex mitochondria:
maximal respiration
Maximal Reserve BHI
R p R p R p
Pearson: 0.59 0.04 0.49 0.09 0.59 0.03
Partial correlations
Age 0.62 0.03 0.56 0.06 0.43 0.16
Body weight 0.62 0.03 0.56 0.06 0.42 0.17
Plasma glucose 0.65 0.02 0.65 0.02 0.58 0.05
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(R = 0 59, p = 0 03). This relationship was maintained when
controlling for glucose; however, only trends are maintained
when controlling for age and body weight.
Relationships between platelet respiratory parameters
and the maximal respiration of mitochondria isolated from
the frontal cortex tissue are summarized in Table 4. A
representative regression plot is shown in Figure 2. For
platelets, BHIwas significantly positively correlatedwithbrain
mitochondrial maximal respiration (R = 0 63, p = 0 01), even
when controlling for age, body weight, and plasma glucose
concentration. Interestingly, maximal OCR and reserve
capacity were not associated.
3.3. Pearson and Partial Correlations between Monocyte/
Platelet Respiration and Brain Glucose Metabolism. A subset
of 5 animals was analyzed for both CD14+ respiration and
brain metabolism by FDG-PET (summarized in Table 5). A
subset of 7 animals was analyzed for both platelet respiration
and brain metabolism (summarized in Table 6). Strong
trends for positive correlations between monocyte BHI and
FDG-PET were observed when controlling for age; statistical
significance was reached for the amygdala and frontal cortex
regions (R = 0 96, p = 0 04; R = 0 96, p = 0 04; resp.). For
platelets, reserve respiratory capacity and BHI were positively
correlated with FDG-PET measures in all brain areas
examined. Strong trends are apparent throughout, and statisti-
cally significant relationships were observed between reserve
capacity with the anterior cingulate cortex (Brodmann area
32), amygdala, and anterior hippocampus (R = 0 80, p = 0 03;
R = 0 79, p = 0 04; R = 0 78, p = 0 04; resp.). These relation-
ships remained statistically significant when controlling for
body weight.
4. Discussion
Blood-based bioenergetic profiling has been proposed to be a
minimally invasive indicator of mitochondrial health [9, 38].
While respirometric profiling of circulating cells is now being
utilized in various human studies, little is known about how
these measures relate to the bioenergetic capacity of various
tissues of interest. Using a nonhuman primate model, we
recently reported that the bioenergetic capacity of circulating
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Figure 1: Associations of CD14+ monocyte (a) maximal respiration (pmol/min/250,000 cells) and (b) BHI with the maximal respiratory
capacity of frontal cortex mitochondria (pmol/min/5 μg mitochondrial protein). Pearson’s correlations and p values for each association
are shown.
Table 4: Pearson and partial correlations between platelet and
isolated brain mitochondrial respiration.
Frontal cortex mitochondria:
maximal respiration
Maximal Reserve BHI
R p R p R p
Pearson −0.34 0.21 −0.05 0.86 0.63 0.01
Partial Correlations
Age −0.28 0.33 −0.01 0.98 0.67 0.01
Body weight −0.33 0.25 −0.10 0.73 0.58 0.03
Plasma glucose −0.31 0.28 −0.00 0.99 0.65 0.01
R = 0.63500
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Figure 2: Association of platelet BHI with the maximal
respiratory capacity of frontal cortex mitochondria (pmol/min/
5 μg mitochondrial protein). Pearson’s correlation and p value
are shown.
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cells is significantly positively related to skeletal and cardiac
muscle bioenergetics. In this report, we focus on the brain,
the organ with the highest metabolic demand. We show for
the first time significant positive correlations between con-
temporaneous blood cell and brain mitochondrial respirom-
etry. Furthermore, brain glucose metabolism assessed by
FDG-PET imaging was similarly positively associated with
the bioenergetic profile of circulating blood cells.
Mitochondrial dysfunction is apparent in the patho-
physiology of various diseases and is widely recognized to
be a potential target for intervention. Bioenergetic deficits
may be the result of genetic abnormalities, acute disrup-
tions, or accumulated damage as is the case with chronic
diseases, including those associated with aging. Neuronal
mitochondrial dysfunction is particularly damaging, likely
due to the high metabolic demands of the brain. Numerous
studies have linked mitochondrial alterations to the devel-
opment of AD. Neuronal Aβ has been shown to directly
interact with mitochondria to inhibit complex IV of the
ETC [49]. Alterations in mitochondrial quality control pro-
cesses, such as mitochondrial fusion, fission, and autophagy,
are also associated with neurodegeneration and specifically
to AD [50–57]. Specificmitochondrial DNA (mtDNA)muta-
tions are related to cognitive function, AD status, and risk
[58–62]. These alterations can all contribute to bioenergetic
decline and alterations in brain metabolism associated with
AD. As a result, measures of brain metabolism are currently
being utilized to study the pathophysiology of AD and are
Table 5: Pearson and partial correlations between monocyte
respiration and brain glucose metabolism (FDG-PET).
FDG-PET: brain region
Maximal Reserve BHI
R p R p R p
Pearson
Area 24 0.46 0.44 0.26 0.67 0.40 0.50
Area 25 0.39 0.51 0.19 0.75 0.41 0.50
Area 32 0.50 0.39 0.28 0.64 0.43 0.46
Amygdala 0.42 0.48 0.23 0.71 0.28 0.65
Ant. hippocampus 0.46 0.44 0.31 0.61 0.26 0.68
Post. hippocampus 0.39 0.52 0.27 0.66 0.18 0.77
Frontal cortex 0.32 0.59 0.06 0.93 0.37 0.55
Partial for age
Area 24 0.46 0.54 0.16 0.84 0.92 0.08
Area 25 0.38 0.62 0.08 0.92 0.89 0.11
Area 32 0.50 0.50 0.19 0.81 0.93 0.07
Amygdala 0.45 0.55 0.08 0.92 0.96 0.04
Ant. hippocampus 0.49 0.51 0.20 0.80 0.91 0.09
Post. hippocampus 0.42 0.58 0.13 0.87 0.89 0.11
Frontal cortex 0.31 0.69 −0.12 0.88 0.96 0.04
Partial for weight
Area 24 0.11 0.89 0.04 0.96 0.36 0.64
Area 25 0.05 0.95 −0.02 0.98 0.36 0.64
Area 32 0.16 0.84 0.06 0.94 0.40 0.60
Amygdala −0.07 0.93 −0.07 0.93 0.20 0.80
Ant. hippocampus 0.07 0.93 0.10 0.90 0.17 0.83
Post. hippocampus −0.03 0.97 0.04 0.96 0.07 0.93
Frontal cortex −0.26 0.74 −0.35 0.65 0.32 0.68
Partial for plasma glucose
Area 24 0.46 0.54 0.28 0.72 0.41 0.59
Area 25 0.40 0.61 0.21 0.79 0.41 0.59
Area 32 0.51 0.50 0.31 0.69 0.45 0.56
Amygdala 0.46 0.55 0.32 0.68 0.33 0.68
Ant. hippocampus 0.47 0.53 0.36 0.64 0.27 0.73
Post. hippocampus 0.41 0.59 0.33 0.67 0.20 0.80
Frontal cortex 0.39 0.61 0.18 0.82 0.45 0.55
Areas 24, 25, and 32 = Brodmann areas (anterior cingulate cortex);
Ant. = anterior; Post. = posterior; N = 5.
Table 6: Pearson and partial correlations between platelet
respiration and brain glucose metabolism (FDG-PET).
FDG-PET: brain region
Maximal Reserve BHI
R p R p R p
Pearson
Area 24 0.55 0.20 0.72 0.07 0.74 0.06
Area 25 0.50 0.25 0.67 0.10 0.73 0.06
Area 32 0.65 0.11 0.80 0.03 0.75 0.05
Amygdala 0.67 0.10 0.79 0.04 0.70 0.08
Ant. hippocampus 0.64 0.12 0.78 0.04 0.74 0.06
Post. hippocampus 0.59 0.16 0.73 0.06 0.72 0.07
Frontal cortex 0.56 0.19 0.68 0.09 0.58 0.17
Partial for age
Area 24 0.47 0.35 0.67 0.14 0.70 0.12
Area 25 0.41 0.42 0.62 0.19 0.69 0.13
Area 32 0.57 0.24 0.76 0.08 0.70 0.12
Amygdala 0.54 0.27 0.71 0.11 0.58 0.22
Ant. hippocampus 0.51 0.30 0.71 0.12 0.65 0.17
Post. hippocampus 0.43 0.39 0.64 0.17 0.60 0.21
Frontal cortex 0.45 0.38 0.60 0.21 0.47 0.35
Partial for weight
Area 24 0.66 0.15 0.79 0.06 0.76 0.08
Area 25 0.60 0.21 0.74 0.10 0.74 0.09
Area 32 0.72 0.11 0.83 0.04 0.75 0.09
Amygdala 0.72 0.10 0.81 0.05 0.70 0.12
Ant. hippocampus 0.70 0.12 0.81 0.05 0.74 0.09
Post. hippocampus 0.66 0.16 0.77 0.08 0.72 0.11
Frontal cortex 0.66 0.15 0.74 0.09 0.58 0.23
Partial for plasma glucose
Area 24 0.57 0.25 0.73 0.10 0.74 0.09
Area 25 0.50 0.31 0.68 0.14 0.73 0.10
Area 32 0.65 0.16 0.80 0.06 0.75 0.09
Amygdala 0.68 0.14 0.80 0.06 0.71 0.12
Ant. hippocampus 0.64 0.17 0.78 0.07 0.74 0.09
Post. hippocampus 0.60 0.21 0.74 0.09 0.72 0.11
Frontal cortex 0.58 0.22 0.72 0.11 0.60 0.21
Areas 24, 25, and 32 = Brodmann areas (anterior cingulate cortex);
Ant. = anterior; post. = posterior; N = 7.
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widely recognized to have important diagnostic implications.
The study reported here provides the first evidence suggesting
that brain mitochondrial metabolism may be related to the
bioenergetic profiles of blood cells.
Previous studies employing blood cell respirometry have
focused on heterogeneous cell populations such as mixed
peripheral blood mononuclear cells (PBMCs). In order to
avoid the potential confounding effects of changes in PBMC
cellular composition, this study focused on purified CD14+
monocytes. It is notable that a recent large-scale study of
CD14+ monocytes from 1264 individuals reported that
networks of genes related to oxidative phosphorylation and
mitochondrial protein synthesis were differentially expressed
based on chronological age [63]. We also performed respira-
tory analyses on platelets which are readily available and easy
to isolate. Several groups are already exploring the potential
utility of platelets in the diagnosis of diseases such as AD.
Moreover, a recent study has reported that platelet bioener-
getic capacity is related to AD status [34].
Blood-based bioenergetic profiling is not a surrogate for
direct measures of brain metabolism. Rather, it may serve
as a cost-effective screening tool to identify patients who
may be more likely to exhibit neuronal bioenergetic deficits,
based on systemic changes in mitochondria function. Our
results indicating that blood-based bioenergetic profiling is
related to FDG-PET measures of brain glucose metabolism
were obtained from a small subset of primates and should
be considered preliminary. A large-scale study is underway
to confirm these findings in human subjects.
Our predetermined selection criteria were focused on
maximizing differences in age and cardiometabolic health
between animals. Hence, we include analyses controlling
for age, body weight, and blood glucose in this report. Our
sample size is not adequate to study the individual or interac-
tive effects of each of these parameters. As designed, differ-
ences in cardiometabolic health were apparent across our
younger as well as older animals. Indeed, comparing body
weight and blood glucose between younger and older animals
showed no statistical significance and a high level of variabil-
ity. Larger scale future studies are required in order to deter-
mine how age, obesity, and insulin sensitivity/resistance are
individually related to blood and brain bioenergetics.
5. Conclusions
Our data provide evidence that blood-based bioenergetic
profiling can serve as a minimally invasive measure of
systemic bioenergetic capacity that is positively related to
measures of brain mitochondrial function and metabolism.
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